Paris-based startup Nabla has successfully raised $24 million in its latest Series B funding round, a significant step towards expanding its innovative AI-powered tool. The tool, known as Nabla Copilot, is designed to generate clinical notes from patient consultations, aiding doctors in summarizing essential elements such as patient medical history, symptoms, diagnosis, and prescriptions. The funding, led by Cathay Innovation and Zebox, brings Nabla’s total funding to $43 million and highlights the growing impact of AI in addressing healthcare challenges globally.
The success follows the recent launch of Nabla Copilot in March, marking a pivotal moment for the company and underlining the transformative potential of AI in overcoming healthcare system challenges. The company envisions a future where clinicians can focus on patients while Nabla’s AI collaborates on delegated tasks, ultimately leading to happier and stress-free healthcare professionals.
Nabla Copilot has gained traction, with 20,000 clinicians globally benefitting from its integration with major Electronic Health Record (EHR) systems like Epic and Nextgen. Currently managing over 3 million consultations annually in three languages, Copilot streamlines clinical documentation, allowing practitioners to save significant time and enhance overall efficiency.
The Series B funding will further accelerate Nabla’s expansion into the US market, building on its success in Europe. Nabla has already made significant strides in the US, establishing partnerships such as the recent collaboration with healthcare provider Kaiser Permanente, aiming to deploy Copilot to 10,000 physicians across Northern California.
Nabla’s AI assistant, Copilot, is a testament to the power of AI in addressing real-world challenges. By automating the note-taking process during clinical consultations, Copilot not only saves time but also contributes to improving the overall quality of healthcare. With a valuation now reaching $180 million, Nabla is poised to make substantial contributions to the future of healthcare by leveraging AI to support healthcare teams in various aspects beyond clinical documentation.
The success of Nabla’s fundraising efforts highlights the growing recognition of AI’s role in transforming healthcare, with investors showing confidence in the company’s mission to enhance the lives of both clinicians and patients. As Nabla continues its journey, the focus remains on providing efficient and effective solutions for the evolving landscape of healthcare, demonstrating the significant impact AI can have on the industry.
